GlassScriptPhysician profile
David M Coussens
NPI 1538134283
$134,118.58
in general payments reported to CMS, 2019-2025
38 companies · $1,023 in 2025
The $1,023 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39K · 2020: $27K · 2021: $23K · 2022: $25K · 2023: $3,752 · 2024: $15K · 2025: $1,023.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $4,221 · Travel and Lodging: $1,655.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,500.00 |
| Food and Beverage | $4,221.11 |
| Travel and Lodging | $1,654.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cryo Specialty Medical, LLC | $124,500.00 | 2019-2024 | |
| Angiodynamics, INC. | $2,509.92 | 2022-2024 | Nanoknife |
| Astellas Pharma US INC | $824.36 | 2019-2024 | Xtandi |
| Boston Scientific Corporation | $529.06 | 2019-2024 | Spaceoar Vue System - 10ml |
| Rochester Medical Corporation | $457.54 | 2020-2022 | |
| Coloplast Corp | $438.56 | 2020-2025 | Titan |
| Abbvie INC. | $426.13 | 2019-2025 | Lupron Depot, Botox, Avycaz |
| Sumitomo Pharma America, INC. | $398.65 | 2023-2025 | Orgovyx, Gemtesa |
| Dendreon Pharmaceuticals LLC | $388.01 | 2019-2025 | Provenge |
| Novartis Pharmaceuticals Corporation | $373.57 | 2023-2025 | |
| Pfizer INC. | $363.79 | 2019-2025 | |
| Janssen Biotech, INC. | $309.11 | 2019-2025 | Erleada, Akeega |
| Cipla USA INC. | $246.05 | 2023 | |
| Myriad Genetic Laboratories, INC. | $242.56 | 2020-2025 | Myrisk, Prolaris |
| Myovant Sciences INC. | $234.92 | 2021-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verity Pharmaceuticals INC. | $234.81 | 2023-2025 | Trelstar, Tlando |
| Amgen INC. | $152.21 | 2019-2023 | Xgeva |
| Terumo Medical Corporation | $140.28 | 2025 | Azur Cx Detachable, Angio-Seal |
| Bayer Healthcare Pharmaceuticals INC. | $134.11 | 2019-2024 | |
| Endo Pharmaceuticals INC. | $124.67 | 2019-2020 | |
| Accord Healthcare, INC. | $121.27 | 2023-2025 | |
| Blue Earth Diagnostics | $116.54 | 2020-2022 | |
| Axonics, INC. | $116.04 | 2022-2023 | Axonics |
| Teleflex LLC | $101.47 | 2024-2025 | Barrigel, Urolift |
| Allergan, INC. | $88.59 | 2019-2020 | |
| C. R. Bard, INC. & Subsidiaries | $84.00 | 2019-2023 | Bard Urinary Drainage Bag |
| Tolmar, INC. | $77.57 | 2023 | |
| Merck Sharp & Dohme LLC | $56.16 | 2021-2022 | |
| Antares Pharma, INC. | $51.23 | 2024-2025 | Xyosted |
| Ferring Pharmaceuticals INC. | $49.09 | 2019-2020 | |
| Palette Life Sciences, INC. | $46.59 | 2022 | |
| Foundation Medicine, INC. | $44.74 | 2019 | |
| Civco Medical Instruments | $29.49 | 2025 | |
| Medtronic USA, INC. | $24.76 | 2020 | |
| Janssen Scientific Affairs, LLC | $21.55 | 2019 | |
| Cure Medical LLC | $20.66 | 2020 | |
| Urogen Pharma, INC. | $20.46 | 2022 | |
| Neotract INC. | $20.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$394,464.73 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Coussens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.